iRhythm Technologies, Inc.
182.67-0.04 (-0.02%)
Oct 28, 4:00:02 PM EDT · NasdaqGS · IRTC · USD
Key Stats
Market Cap
5.87BP/E (TTM)
-Basic EPS (TTM)
-2.92Dividend Yield
0%Recent Filings
8-K
Q2 revenue jumps 26%
iRhythm Technologies reported Q2 2025 revenue of $186.7 million, up 26.1% from last year, fueled by strong demand for Zio monitoring services, Zio AT adoption, and international expansion. Gross margin improved to 71.2%, while net loss narrowed to $14.2 million from $20.1 million, reflecting operational leverage. The company raised full-year guidance to $720–730 million in revenue and 8.0–8.5% adjusted EBITDA margin. Growth surges, yet litigation costs linger.
10-Q
Q2 FY2025 results
iRhythm Technologies posted solid Q2 FY2025 results, with revenue climbing 26% year-over-year to $186.7M from $148.0M, fueled by higher volumes in Zio AT services amid new customer wins, while gross margin held steady at 71.2% despite rising material and labor costs. Operating loss narrowed to $18.7M from $23.0M, thanks to better topline momentum offsetting elevated SG&A from headcount growth and $3.0M in patent litigation fees; net loss improved 29% to $14.2M or $(0.44) per diluted share on 31.99M shares. Cash from operations turned positive at $19.8M YTD, bolstering liquidity to $545.5M in cash and equivalents, with $648.0M in long-term convertible notes due 2029 at 1.50% and no revolver. A $2.5M impairment hit internal software tied to the shelved Zio Watch project, yet BioIntelliSense milestone progress advances pulse oximetry tech integration. Patent suits from Baxter units loom as a key risk, potentially hiking legal costs and distracting focus.
8-K
Board retires veterans, appoints experts
iRhythm Technologies saw two veteran board members, Mark Rubash and Ralph Snyderman, retire effective July 7, 2025, after nearly a decade of service steering the company through growth and innovation in digital health. The board swiftly appointed Karen McGinnis and Kevin O'Boyle as independent directors, both joining the Audit Committee with O'Boyle also on Nominating and Governance; they received $300,000 in restricted stock units vesting over three years. New blood bolsters financial and operational expertise. Yet board refreshment demands seamless integration.
8-K
Annual meeting results strong
iRhythm Technologies held its 2025 Annual Meeting on May 28, with 94.1% of shares represented. All eight director nominees, including Quentin Blackford and Abhijit Talwalkar, won election despite some withheld votes for Bruce Bodaken. PricewaterhouseCoopers' auditor role was ratified overwhelmingly, while 87% backed executive pay in the advisory vote. Strong turnout signals investor alignment.
8-K
Q1 revenue surges 20%
iRhythm Technologies reported Q1 2025 revenue of $158.7 million, up 20.3% from last year, fueled by Zio service demand and the Japan launch. Gross margin climbed to 68.8%, thanks to volume leverage, while net loss narrowed to $30.7 million from $45.7 million. Momentum builds. The company raised full-year guidance to $690–700 million in revenue and 7.5–8.5% adjusted EBITDA margin, yet patent litigation costs linger.
IPO
Website
Employees
Sector
Industry
ADGM
Adagio Medical Holdings, Inc
1.27-0.03
BEAT
Heartbeam, Inc.
1.58-0.03
BTCY
Biotricity Inc.
0.59-0.06
DXCM
DexCom, Inc.
69.23-1.40
IRIX
IRIDEX Corporation
1.01-0.05
IRMD
iRadimed Corporation
79.79+2.06
IRME
IR-Med Inc.
0.03+0.00
RMD
ResMed Inc.
256.57-2.64
RTGN
RETINALGENIX TECHNOLOGIES INC
3.75+0.00
SENS
Senseonics Holdings, Inc.
7.20-0.24